A detailed history of D. E. Shaw & Co., Inc. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 496,543 shares of CCCC stock, worth $2.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
496,543
Previous 243,638 103.8%
Holding current value
$2.26 Million
Previous $1.38 Million 194.77%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$5.3 - $11.0 $1.34 Million - $2.78 Million
252,905 Added 103.8%
496,543 $4.06 Million
Q4 2023

Feb 14, 2024

SELL
$1.18 - $6.03 $224,756 - $1.15 Million
-190,472 Reduced 43.88%
243,638 $1.38 Million
Q3 2023

Nov 14, 2023

SELL
$1.81 - $3.89 $153,974 - $330,918
-85,069 Reduced 16.39%
434,110 $807,000
Q2 2023

Aug 14, 2023

BUY
$2.75 - $3.77 $893,799 - $1.23 Million
325,018 Added 167.4%
519,179 $1.43 Million
Q1 2023

May 15, 2023

BUY
$3.1 - $9.02 $335,420 - $975,964
108,200 Added 125.87%
194,161 $609,000
Q4 2022

Feb 14, 2023

SELL
$5.42 - $10.24 $239,135 - $451,799
-44,121 Reduced 33.92%
85,961 $507,000
Q3 2022

Nov 14, 2022

BUY
$8.03 - $12.77 $411,890 - $655,024
51,294 Added 65.1%
130,082 $1.14 Million
Q2 2022

Aug 15, 2022

BUY
$5.06 - $26.46 $398,667 - $2.08 Million
78,788 New
78,788 $594,000
Q1 2022

May 16, 2022

SELL
$19.99 - $33.23 $514,442 - $855,174
-25,735 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$29.39 - $46.86 $465,890 - $742,824
15,852 Added 160.4%
25,735 $829,000
Q3 2021

Nov 15, 2021

SELL
$35.91 - $50.5 $238,765 - $335,774
-6,649 Reduced 40.22%
9,883 $442,000
Q2 2021

Aug 16, 2021

BUY
$30.39 - $42.18 $337,389 - $468,282
11,102 Added 204.46%
16,532 $626,000
Q1 2021

May 17, 2021

SELL
$31.96 - $46.5 $228,322 - $332,196
-7,144 Reduced 56.82%
5,430 $201,000
Q4 2020

Feb 16, 2021

BUY
$22.8 - $37.05 $286,687 - $465,866
12,574 New
12,574 $417,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $223M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.